Merck & Co has agreed to acquire antibiotics specialist Cubist Pharmaceuticals in a cash deal worth about $9.5bn. Merck will pay $8.4bn in cash for Cubist's stock at $102 per share (a 35% premium to the company's average stock price over the previous five days), and the deal includes $1.1bn in net debt.
However, clouds soon gathered after the deal was announced on 8 December 2014, with a judge in the US District...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
